期刊文献+

干扰素α-2b与聚乙二醇干扰素α-2a治疗低病毒载量慢性丙型肝炎快速及早期病毒学应答临床观察 被引量:3

Interferon α-2b and pegylated interferon α-2a in therapy of chronic hepatitis C patients with low viral load:Clinical observation on the rapid and early virological
下载PDF
导出
摘要 目的研究干扰素类型在低病毒载量慢性丙型肝炎抗病毒治疗应答的影响。方法选择120例慢性丙型肝炎患者为研究对象,将120例患者分为聚乙二醇干扰素α-2a(派罗欣,Peg-IFN)组58例和普通干扰素α2b(凯因益生)组62例。所有患者用干扰素联合利巴韦林抗病毒治疗。Peg-IFN组选用180μg每周注射1次,普通干扰素组为600MU隔日注射1次。利巴韦林使用剂量900~1 200mg/d。疗程:达RVR之后再应用24周;达EVR之后再应用36周;对于12周未达EVR者再应用48周。对抗病毒治疗的应答情况与干扰素类型及丙肝病毒载量的关系进行回顾性分析。结果两组中,普通干扰素组RVR获得率为79%,EVR获得率为85.4%,派罗欣组的RVR获得率为81%,EVR获得率为89.6%。对于RVR的获得,x^2=0.009,P>0.05,对于EVR的获得,x^2=0.036,P>0.05,对于SVR的获得,x^2=0.010,P>0.05,组间比较差异无统计学意义。结论在病毒载量较低的情况下,聚乙二醇干扰素α-2a与普通干扰素α-2b抗病毒治疗的RVR、EVR、SVR获得率差异无统计学意义。 Objective To observe the response of chronic hepatitis C patients with low viral load to antiviral treatment by different interferon(I FN) modality.Methods 120 patients with chronic hepatitis C were assigned to Peg-IFN group(n=58,treated with Peginterferon alfa-2a injection in dose of 180μg once a week)and recombinant human interferon α—2b injection group(n=62,administered in dose of 600 MU once every other day),and the two groups were given additional dosage of ribavirin by 900-1200 mg/d.The treatment course was as follows:24 weeks were extended after rapid virological response(RVR),and 36 weeks after early virological response(EVR).For patients failed to meet EVR by the 12 th week,48 weeks were extended.The data were retrospectively analyzed on response to antiviral treatment,interferon modality and final viral load after treatment.Results RVR and EVR were 79%and 85.4%for the patients treated with recombinant human interferon α-2b injection,and 81%,and 89.6%for Peg-IFN group,respectively(x^2 = 0.009,P0.05;x^2 =0.036,P 0.05).There was no significance between groups regarding sustained virological response(SVR)(x^2 =0.010,P0.05).Conclusion Interferon α-2b and pegylated interferon α-2a may produce similar effects on chronic hepatitis C patients with lower viral load by statistical estimation of RVR,EVR and SVR.
作者 徐菁 欧亚非
出处 《热带病与寄生虫学》 2014年第4期209-211,共3页 Journal of Tropical Diseases and Parasitology
关键词 丙型肝炎 聚乙二醇干扰素Α-2A 普通干扰素α-2b 病毒学应答 Chronic hepatitis C Pegylated interferon α-2a Recombinant human interferon α-2b Virological response
  • 相关文献

参考文献8

  • 1何伶俐,陈竹,陈杨,徐辉,唐红,雷秉钧,雷学忠.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的疗效及其影响因素[J].中华肝脏病杂志,2011,19(1):34-37. 被引量:36
  • 2Ferenci P, Fried Mw, Shiftman ML, et al. Predicting sus- tained viroiogicalresponses in chronic hepatitis C patients treated withpeginterferon alfa-2a(40 KD) /ribavirin. JHepatol, 2005,43 : 425-433.
  • 3Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virologicalresponse after treatment with peginte rferon-2a (pegasys) alone or in combination with ribavirin(copegus): 5-year foUowup and the criteria of a cure. J Hepatology, 2006, 46(Suppl 1): S3.
  • 4丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 5Jensen DM, Morgan Tt(, MarceUin P, et al. Early identifi- cation of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a(40kd)/ribavirin therapy. Hepatolo- gy, 2006, 43: 954-960.
  • 6Davis GL. Monitoring of viral levels during therapy of hepa- titis C. Hepatology, 2002, 36(Suppi 1):S145-151.
  • 7Zeuzem S, Buti M, Ferenci E, et al. Efficacy of 24 weeks treatment with peginterferon aLfa-2b plus ribavirin in pa- tients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 2006, 44: 97-103.
  • 8Yu Jw, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sus- tained virological response in HCV patients treated with pe- gylated interferon alpha-2a and ribavifin. J Gastroenterol Hepatol, 2007, 22(6): 832-836.

二级参考文献19

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 3Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 4Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 5Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 6Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 7Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 8Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 9Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 10Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.

共引文献763

同被引文献23

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部